Today, we announced that the first participant has been dosed in RESTORE, our Phase 3 registrational study evaluating NVG-291 in chronic spinal cord injury. Read more: nervgen.com/nervgen-announce… #SCI #SpinalCordInjury

The SCI community in the Times Square spotlight. Thank you, @Nasdaq, for recognizing #SCIAwarenessMonth. Help keep the SCI community voice at the center of progress. Join the free, virtual SCI PFDD meeting Sept. 29: scipfdd.org/register

On September 30th, NVG-291 will be in focus at NervGen’s inaugural R&D Day. Four leading experts in SCI clinical care, outcome assessment, translational research and community advocacy will join NervGen management for an in-depth program review and Q&A. Register: edge.media-server.com/mmc/p/…

Did you know? A recent analysis of structured community feedback led by NASCIC and published in Spinal Cord found that 87% of participants with traumatic cervical SCI linked potential treatment success to functional tasks—not muscle grading alone. Learn more: doi.org/10.1038/s41393-026-0…

On #WorldSCIDay, we join @iscosmeetings in marking 10 years of turning awareness into action on SCI prevention. Individuals living with SCI can help guide the next decade by sharing their perspectives at the free virtual Sept. 29 SCI PFDD meeting: scipfdd.org/register

More than 15 million people worldwide live with SCI. Behind every number is a person with individual experiences, priorities and goals. This #SCIAwarenessMonth, join the conversation and register for the Patient-Focused Drug Development meeting on SCI: scipfdd.org

September is #SCIAwarenessMonth. Through the month, we'll highlight the priorities of individuals living with SCI and the science driving our work to enable the nervous system to repair itself — including the Sept. 29 @SCIPFDD Meeting. Register: scipfdd.org/register

NervGen today reported financial results for the second quarter of 2026 and provided business updates. Read the full news release: bit.ly/4qhO5hZ $NGEN #SCI #SpinalCordInjury #InvestorRelations

NervGen has a new website! NervGen's redesigned website is live — a clearer look at our science, our pipeline, and our mission to transform the lives of individuals living with spinal cord injury and nervous system damage. Take a look at nervgen.com

NervGen today announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study. Read the full news release: nervgen.com/nervgen-announce… #SCI #SpinalCordInjury

NervGen today reported financial results for the first quarter ended March 31, 2026, and provided business updates. Read the full news release: nervgen.com/nervgen-reports-… #SCI #SpinalCordInjury

NervGen today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer to lead financial strategy and operations. nervgen.com/nervgen-pharma-s… #SCI #SpinalCordInjury

NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in a fireside chat during the virtual H.C. Wainwright “HCW@Home” series and present at the 2026 Bloom Burton & Co. Healthcare Investor Conference. nervgen.com/nervgen-pharma-t… #SCI

NervGen today announced the completion of a successful End-of-Phase 2 (EOP2) meeting and alignment on RESTORE, the Company’s Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia. RESTORE initiation remains on-track for mid-2026, with study initiation activities underway. Read the full news release: nervgen.com/nervgen-pharma-a… #SCI #SpinalCordInjury

NervGen Pharma today reported its full year 2025 financial results and provided business updates. Read the full news release: nervgen.com/nervgen-pharma-r… #SCI #SpinalCordInjury

NervGen’s CEO, Dr. Adam Rogers, joined @biotechnation to share the story behind NVG-291, from Dr. Jerry Silver’s pioneering research and Harold Punnett’s founding vision to what NervGen’s CONNECT SCI clinical data now shows is possible for individuals living with chronic spinal cord injury. biotechnation.com/episodes/r… #SCI #SpinalCordInjury

NervGen Pharma today announced that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026. The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN,” and no action is required by shareholders. All shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq. Read the full news release: nervgen.com/nervgen-pharma-a… #SCI #SpinalCordInjury

NervGen today appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs. nervgen.com/nervgen-pharma-a… #SCI

NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in multiple upcoming investor conferences. nervgen.com/nervgen-pharma-t… #SCI

NervGen today announced it will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC. nervgen.com/nervgen-pharma-t… #SCI #SpinalCordInjury #CNS #NeuroRepair #Biotech